WAT Waters Corporation Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
13:00
Aug 05
Aug 05
DSA bookings and book-to-bill hit their highest level in nearly four years (Q3 2022), signalling the start of an industry-wide recovery in preclinical demand, earlier than many expected. — Strong DSA demand may indicate a broader CRO recovery trend; competitors may also see improvements later in 2026.
MED
12:00
Aug 04
Aug 04
Management raised every component of FY guidance, citing strong momentum across the portfolio and broad-based end-market recovery, indicating a bullish outlook for the remainder of the year.
HIGH
13:00
Jul 28
Jul 28
Although Evoqua is now part of Xylem, its integration is directly credited for enabling Xylem's growth and margin expansion in industrial markets.
HIGH
12:00
May 07
May 07
The completed combination with Waters' life sciences business is a structural change for BD, but this mention focuses on the execution being ahead of schedule, not on Waters' own outlook.
HIGH
23:54
May 05
May 05
Waters Corp strong life science play
Waters Corporation had an excellent quarter, driven by regulated pharma applications, GLP-1 manufacturing, and strong China pharma growth, making it the best S&P performer today.
HIGH
13:17
May 05
May 05
TheLAPurchaser highlights Udit's positive influence on Waters Corporation.
TheLAPurchaser highlights Udit's positive influence on Waters Corporation, suggesting renewed momentum in the life sciences sector.
HIGH
14:02
Mar 17
Mar 17
The author suggests that the life sciences sector has reached a market floor.
21:30
Feb 25
Feb 25
Agilent's LC instrument replacement cycle is showing 2x peer growth, driven by the Infinity Tree system, signaling a clear share gain over Waters and Thermo Fisher in high-performance liquid chromatography. — A sustained 2x growth differential in a major instrument category would directly pressure Waters' core business and indicate a structural shift in the competitive landscape.
HIGH
13:30
Feb 09
Feb 09
Management guides to strong industry-leading 5.3% growth for the combined company, with multiple embedded conservative assumptions (e.g., excluding pricing improvements, reshoring, and China stimulus) leaving room for upside.
HIGH
13:00
Feb 09
Feb 09
BD is closing the spin-merger of its life sciences business with Waters, which will create a new combined entity and provide BD with a $4B cash distribution.
HIGH
About WAT Analyst Coverage
Buzzberg tracks WAT (Waters Corporation) across 4 sources. 2 bullish vs 0 bearish calls from 10 analysts. Sentiment: predominantly bullish (18%). 11 total trade ideas tracked. Latest voices: Birgit Girshick, Amol Chaubal, Matthew Pine.